Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
60 Degrees Pharma survey suggests babesiosis affects up to 3M Americans—vastly more than CDC data—and may underlie millions of chronic fatigue cases.
-
60 Degrees Pharma (SXTP) announces a 1-for-5 reverse stock split, effective Feb. 24, 2025, to meet Nasdaq's $1.00 minimum bid price requirement.
-
60 Degrees Pharma will import KODATEF® from Australia to ensure U.S. tafenoquine supply, addressing rising ARAKODA® demand.
-
60 Degrees Pharma closed a $1.075M registered direct offering, raising $2.118M YTD to fund operations. H.C. Wainwright & Co. acted as placement agent.
-
60 Degrees Pharma (SXTP) announces a $1.075M registered direct offering, issuing stock and warrants to fund working capital and corporate initiatives.
-
60 Degrees Pharma (Nasdaq: SXTP) closed a $1.043M registered direct offering, issuing common stock and short-term warrants to fund working capital.
-
60 Degrees Pharma (SXTP) announces a $1.043M registered direct offering, issuing stock and warrants to fund working capital and corporate initiatives.
-
60 Degrees Pharmaceuticals announces IRB approval for Phase II study of tafenoquine for chronic babesiosis, with enrollment starting Q3 2025.
-
60 Degrees Pharma (Nasdaq: SXTP) begins enrolling patients in a clinical study to evaluate tafenoquine for persistent, relapsing babesiosis treatment.
-
60 Degrees Pharma and Tufts MC partner to develop tafenoquine for babesiosis, co-own patents, and aim for FDA approval to address unmet medical needs.